Genetic variation in RNASEL associated with prostate cancer risk and progression.

Variation in genes contributing to the host immune response may mediate the relationship between inflammation and prostate carcinogenesis. RNASEL at chromosome 1q25 encodes ribonuclease L, part of the interferon-mediated immune response to viral infection. We therefore investigated the association between variation in RNASEL and prostate cancer risk and progression in a study of 1286 cases and 1264 controls nested within the prospective Physicians' Health Study. Eleven single-nucleotide polymorphisms (SNPs) were selected using the web-based 'Tagger' in the HapMap CEPH panel (Utah residents of Northern and Western European Ancestry). Unconditional logistic regression models assessed the relationship between each SNP and incident advanced stage (T(3)/T(4), T(0)-T(4)/M(1) and lethal disease) and high Gleason grade (>/=7) prostate cancer. Further analyses were stratified by calendar year of diagnosis. Cox proportional hazards models examined the relationship between genotype and prostate cancer-specific survival. We also explored associations between genotype and serum inflammatory biomarkers interleukin-6 (IL-6), C-reactive protein (CRP) and tumor necrosis factor-alpha receptor 2 using linear regression. Individuals homozygous for the variant allele of rs12757998 had an increased risk of prostate cancer [AA versus GG; odds ratio (OR): 1.63, 95% confidence interval (CI): 1.18-2.25), and more specifically, high-grade tumors (OR: 1.90, 95% CI: 1.25-2.89). The same genotype was associated with increased CRP (P = 0.02) and IL-6 (P = 0.05) levels. Missense mutations R462Q and D541E were associated with an increased risk of advanced stage disease only in the pre-prostate-specific antigen era. There were no significant associations with survival. The results of this study support a link between RNASEL and prostate cancer and suggest that the association may be mediated through inflammation. These novel findings warrant replication in future studies.

[1]  I. Thompson,et al.  Single and Multivariate Associations of MSR1, ELAC2, and RNASEL with Prostate Cancer in an Ethnic Diverse Cohort of Men , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[2]  Kari Stefansson,et al.  Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility , 2009, Nature Genetics.

[3]  Peter Kraft,et al.  Identification of a new prostate cancer susceptibility locus on chromosome 8q24 , 2009, Nature Genetics.

[4]  Kevin M. Bradley,et al.  Genetic Variants and Prostate Cancer Risk: Candidate Replication and Exploration of Viral Restriction Genes , 2009, Cancer Epidemiology Biomarkers & Prevention.

[5]  P. Kraft,et al.  Circulating prediagnostic interleukin‐6 and C‐reactive protein and prostate cancer incidence and mortality , 2009, International journal of cancer.

[6]  W. Isaacs,et al.  Association of IL10 and Other immune response‐ and obesity‐related genes with prostate cancer in CLUE II , 2009, The Prostate.

[7]  C. Carlson,et al.  C-reactive protein, interleukin-6, and prostate cancer risk in men aged 65 years and older , 2009, Cancer Causes & Control.

[8]  C. Ulrich,et al.  Correlates of circulating C-reactive protein and serum amyloid A concentrations in breast cancer survivors , 2009, Breast Cancer Research and Treatment.

[9]  J. Carpten,et al.  Association of HPC2/ELAC2 and RNASEL non‐synonymous variants with prostate cancer risk in African American familial and sporadic cases , 2008, The Prostate.

[10]  M. Aepfelbacher,et al.  Prevalence of human gammaretrovirus XMRV in sporadic prostate cancer. , 2008, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[11]  P. Febbo,et al.  No association between a polymorphic variant of the IRS‐1 gene and prostate cancer risk , 2008, The Prostate.

[12]  M. Mori,et al.  C‐reactive protein as a prognostic marker for men with androgen‐independent prostate cancer , 2008, Cancer.

[13]  B. Crespi,et al.  Molecular Evolution of the Prostate Cancer Susceptibility Locus Rnasel: Evidence for Positive Selection , 2022 .

[14]  L. Kuller,et al.  RNASEL and RNASEL‐inhibitor variation and prostate cancer risk in Afro‐Caribbeans , 2008, The Prostate.

[15]  W. Willett,et al.  Multiple loci identified in a genome-wide association study of prostate cancer , 2008, Nature Genetics.

[16]  R. Silverman,et al.  A scientific journey through the 2-5A/RNase L system. , 2007, Cytokine & growth factor reviews.

[17]  I. Thompson,et al.  Association of RNASEL Variants with Prostate Cancer Risk in Hispanic Caucasians and African Americans , 2007, Clinical Cancer Research.

[18]  A. Jakubowska,et al.  DNA Variation in MSR1, RNASEL and E-Cadherin Genes and Prostate Cancer in Poland , 2007, Urologia Internationalis.

[19]  C. Ryan,et al.  C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer (AIPC): Results from the ASCENT trial , 2007 .

[20]  R. Hayes,et al.  RNASEL Arg462Gln polymorphism and prostate cancer in PLCO , 2007, The Prostate.

[21]  Jianfeng Xu,et al.  Inflammation in prostate carcinogenesis , 2007, Nature Reviews Cancer.

[22]  B. Tai,et al.  RNASEL Gene Polymorphisms and the Risk of Prostate Cancer: a Meta-analysis , 2006, Clinical Cancer Research.

[23]  J. Derisi,et al.  Identification of a Novel Gammaretrovirus in Prostate Tumors of Patients Homozygous for R462Q RNASEL Variant , 2006, PLoS pathogens.

[24]  Hugues Sicotte,et al.  SNP500Cancer: a public resource for sequence validation, assay development, and frequency analysis for genetic variation in candidate genes , 2005, Nucleic Acids Res..

[25]  A. Kibel,et al.  Association of hereditary prostate cancer gene polymorphic variants with sporadic aggressive prostate carcinoma , 2006, The Prostate.

[26]  W. Isaacs,et al.  Prostate carcinogenesis and inflammation: emerging insights. , 2005, Carcinogenesis.

[27]  R. Stock,et al.  C‐reactive protein is significantly associated with prostate‐specific antigen and metastatic disease in prostate cancer , 2005, BJU international.

[28]  T. Rebbeck,et al.  Association of Susceptibility Alleles in ELAC2/HPC2, RNASEL/HPC1, and MSR1 with Prostate Cancer Severity in European American and African American Men , 2005, Cancer Epidemiology Biomarkers & Prevention.

[29]  N. Cook,et al.  C-Reactive Protein Levels Are Not Associated with Increased Risk for Colorectal Cancer in Women , 2005, Annals of Internal Medicine.

[30]  R. Silverman,et al.  HPC1/RNASEL Mediates Apoptosis of Prostate Cancer Cells Treated with 2′,5′-Oligoadenylates, Topoisomerase I Inhibitors, and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand , 2004, Cancer Research.

[31]  T. Erlinger,et al.  C-reactive protein and the risk of incident colorectal cancer. , 2004, JAMA.

[32]  H. Yamanaka,et al.  Role of genetic polymorphisms of the RNASEL gene on familial prostate cancer risk in a Japanese population , 2003, British Journal of Cancer.

[33]  P. Walsh.  A novel founder mutation in the RNASEL gene, 471delAAAG, is associated with prostate cancer in Ashkenazi Jews. , 2003, The Journal of urology.

[34]  J. Witte,et al.  RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases , 2002, Nature Genetics.

[35]  G. Rennert,et al.  A novel founder mutation in the RNASEL gene, 471delAAAG, is associated with prostate cancer in Ashkenazi Jews. , 2002, American journal of human genetics.

[36]  K. Klinger,et al.  Germline mutations in the ribonuclease L gene in families showing linkage with HPC1 , 2002, Nature Genetics.

[37]  M. Kattan,et al.  Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. , 1999, The Journal of urology.

[38]  R. Silverman,et al.  Interferon action and apoptosis are defective in mice devoid of 2′,5′‐oligoadenylate‐dependent RNase L , 1997, The EMBO journal.

[39]  D A Meyers,et al.  Major Susceptibility Locus for Prostate Cancer on Chromosome 1 Suggested by a Genome-Wide Search , 1996, Science.

[40]  M. Stampfer,et al.  Prospective study of sex hormone levels and risk of prostate cancer. , 1996, Journal of the National Cancer Institute.